Physician profile
Sunil J Abraham
NPI 1013161306
$1,500.66
in general payments reported to CMS, 2019-2025
24 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $126 · 2021: $164 · 2022: $126 · 2023: $181 · 2024: $356 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $265.58 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $146.07 | 2023-2025 | |
| Lilly USA, LLC | $132.40 | 2021-2025 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.93 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.90 | 2023-2025 | Xifaxan |
| Abbott Laboratories | $105.99 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $70.01 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novo Nordisk INC | $61.93 | 2019-2021 | |
| Allergan, INC. | $59.60 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $57.96 | 2024-2025 | Zoryve |
| Exact Sciences Corporation | $44.85 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $41.02 | 2020-2022 | |
| Glaxosmithkline, LLC. | $37.97 | 2019-2024 | Shingrix |
| Dexcom, INC. | $36.51 | 2023-2024 | Dexcom G6 Transmitter |
| Harmony Biosciences LLC | $35.28 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $27.91 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $26.96 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.83 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.07 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.80 | 2025 | |
| Verona Pharma, INC. | $15.41 | 2025 | Ohtuvayre |
| Avanir Pharmaceuticals, INC. | $12.86 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.